Genmab
1,719.5 DKK -0.86%12 investors are following this company
Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.
Revenue
16.47B
EBIT %
32.3 %
P/E
25.8
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
GMAB
Daily low / high price
1,691 / 1,727.5
DKK
Market cap
113.72B DKK
Turnover
232.24M DKK
Volume
136K
Latest videos
Financial calendar
Interim report
08.08.2024
Interim report
06.11.2024
ShowingAll content types
Completion of Share Buy-back Program
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools